At Fierce Pharma Engage, one theme stood out: more real-world data and AI are not translating into clearer Medical Affairs decisions.
Medical Affairs teams have more real-world data and more advanced analytics than ever, but decision-making is not getting easier. The core issue is not access to data. It is how evidence is prioritized, interpreted, and applied to real decisions.
This gap between data and decision-making is widening, not closing.
Real-world evidence (RWE), advanced analytics, and enterprise AI are no longer future-state ambitions. They are here, embedded across the product lifecycle.
And yet, for many teams, decision-making hasn’t gotten easier. If anything, it’s gotten more complicated.
The promise of RWE is real. So is the friction.
The panel on “Turning Real-World Data Into Real-World Decisions” highlighted just how central RWE has become. It increasingly informs product differentiation, regulatory confidence, payer engagement, and guideline development.
At the same time, AI is reshaping how teams access and interpret data. Messy real-world datasets are becoming more usable. Literature surveillance is faster. Insights that once took months can now be surfaced in days.
On paper, this is progress.
In practice, many organizations are still struggling to translate that progress into clearer, faster, more confident decisions.
More data isn’t solving the problem
One of the more candid themes from the discussion was this: data overload is becoming a strategic risk.
Teams are:
- collecting more data than they can realistically act on
- delaying decisions while waiting for “complete” evidence
- defaulting to volume instead of prioritization
Somewhere along the way, being “data-driven” started to mean gathering as much information as possible, rather than focusing on what actually moves a decision forward.
The result is a quiet but important shift. Organizations risk becoming data-rich, but insight-poor.
More data does not improve decision-making if the decision itself is not clearly defined. More data does not reduce uncertainty if the underlying question is unclear.
The shift Medical Affairs actually needs
What emerged from the session was not a call for more data, but for a different approach to using it.
The shift is from data collection to decision-led evidence strategy.
The most effective teams are starting in a different place. They are asking:
- What decision are we trying to influence?
- What change are we trying to drive?
- What evidence is actually needed to support that?
From there, data becomes a tool, not the starting point.
This shift toward insight-led strategy requires a few things to come together:
- alignment across Medical Affairs, HEOR, market access, and commercial
- infrastructure that connects data across teams rather than siloing it
- a willingness to iterate, rather than waiting for perfect evidence
- and a continued role for human judgment alongside AI
AI can accelerate analysis. It can surface patterns. It can scale insight generation. But it does not replace the need to ask the right questions or interpret what the answers mean in context.
The missing piece: patient experience
For all the progress in RWE and analytics, one gap still stands out.
Patient perspective is expanding, but it is not consistently integrated into how evidence strategies are built.
Patients today are more informed, more vocal, and more engaged than ever. Social listening, patient-reported outcomes, advisory councils, and digital tools are creating entirely new streams of insight.
These signals can reveal how treatments are experienced in the real world, not just how they perform in controlled settings.
And yet, they are often introduced too late or treated as a separate input rather than a core component of evidence generation.
That is a missed opportunity.
Without patient context, evidence can describe what is happening but fall short of explaining what should change.
Because while data can tell you what is happening, patient experience helps explain why it matters.
Connecting evidence to real-world relevance
The panel reinforced that evidence generation does not end with publication. The real challenge is ensuring that evidence is usable, credible, and relevant to the people making decisions, whether they are clinicians, payers, regulators, or patients themselves.
That requires more than strong data. It requires connection.
- Connecting clinical trial data with real-world outcomes
- Connecting structured datasets with unstructured patient insights
- Connecting cross-functional teams around a shared evidence strategy
- Connecting outputs to how stakeholders actually use information in practice
AI is making it easier to access and organize these inputs at scale. But the organizations pulling ahead are not simply those with the most advanced tools.
They are the ones that can translate complexity into clarity.
Rethinking what “data-driven” really means
There is a tendency to treat data as a kind of safety net. More data should lead to better decisions. More evidence should reduce risk.
But in reality, data can just as easily become a distraction if it is not tied to a clear objective.
A more useful definition of “data-driven” might look like this:
- focused on the decision at hand
- selective about the data that matters
- connected across sources and teams
- grounded in real-world and patient relevance
- and ultimately, actionable
The future of Medical Affairs will not be defined by how much data teams can generate.
It will be defined by how effectively they can turn that data into decisions that make a difference in real life.
As teams rethink how evidence, insight, and patient experience come together, the difference will be in how those inputs are applied to drive clearer decisions.
FAQ
What is real-world evidence (RWE), and why is it important for Medical Affairs?
Real-world evidence refers to clinical and health-related data collected outside of traditional clinical trials, such as electronic health records, registries, and patient-reported outcomes.
For Medical Affairs, RWE plays a critical role in demonstrating product value, informing clinical practice, supporting regulatory decisions, and engaging payers.
How is AI changing the use of real-world data in pharma?
AI is helping teams process large and complex datasets more efficiently, identify patterns, and accelerate insight generation. It supports analysis of real-world datasets and conducting literature surveillance but still requires human interpretation to ensure relevance, accuracy, context, and ethical use.
What is the biggest challenge with using real-world data today?
The challenge is not access to data, but prioritization and application. Many organizations struggle with data overload, making it difficult to identify which insights are most relevant for decision-making and strategy.
How can Medical Affairs teams make better use of RWE?
Teams can improve their use of RWE by starting with clear strategic questions, focusing on decision-making needs, aligning cross-functional stakeholders, and selecting the most relevant data rather than trying to use all available sources.
Why is patient experience important in evidence strategy?
Patient experience provides critical context that complements clinical and real-world data. It helps organizations understand how treatments affect patients’ lives, improves the relevance of communications, and supports more patient-centered decision-making across the healthcare ecosystem.
